
Human Abl interactor 2 145-153, ILDDIGHGV
Description
About Human Abl interactor 2 145-153, ILDDIGHGV
The Human Abl interactor 2 Peptide (IEDB: 156689) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Abl interactor 2 Peptide, H-ILDDIGHGV-OH (Uniprot: Q9NYB9 aa: 145-153) from JPT is produced under strict quality control and quality management.
Human Abl interactor 2 145-153, ILDDIGHGV - Specifications
- Peptide sequence: H-ILDDIGHGV-OH
- Amount: 1 mg
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Breast cancer, Ovarian cancer, Prostate cancer
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Peptide Synthesis Services!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for Human Abl interactor 2 145-153, ILDDIGHGV
References:
Read References with JPT’s Antigen Peptides
Human Abl interactor 2 145-153, ILDDIGHGV has been described in:
First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients., J Transl Med, 2012 (PMID: 22862954)
Although divergent in residues of the peptide binding site, conserved chimpanzee Patr-AL and polymorphic human HLA-A*02 have overlapping peptide-binding repertoires., J Immunol, 2011 (PMID: 21209280)
A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity., Nature, 2022 (PMID: 34814158)
Documentation
Documentation for Human Abl interactor 2 145-153, ILDDIGHGV
Properties
Properties of Human Abl interactor 2 145-153, ILDDIGHGV
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Breast cancer, Ovarian cancer, Prostate cancer |
Layout: | Freeze-dried in glass vial |
Organism: | Human |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to Human Abl interactor 2 145-153, ILDDIGHGV
Information | Values |
---|---|
Sequence: | H-ILDDIGHGV-OH |
Specifications: | 9mer peptide as TFA salt |